No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Investors Don't See Light At End Of Dong-E-E-Jiao Co.,Ltd.'s (SZSE:000423) Tunnel
Dong-E-E-Jiao (000423.SZ): CHINARES PHARMA has cumulatively increased its Shareholding by 1%.
Gelonghui, February 7th - Dong-E-E-Jiao (000423.SZ) announced that, as of the announcement date, the implementation period of this shareholding plan has passed halfway. CHINARES PHARMA Investment has cumulatively increased its shareholding of the company by 6.424626 million shares through the centralized bidding trading method on the Shenzhen Securities Exchange, accounting for 1.0000% of the company's total share capital.
An Intrinsic Calculation For Dong-E-E-Jiao Co.,Ltd. (SZSE:000423) Suggests It's 33% Undervalued
Dong-E-E-Jiao to See Boost in 2024 Profit
Donga Ejiao: 2024 performance forecast
Dong-E-E-Jiao Co.,Ltd.'s (SZSE:000423) Shareholders Might Be Looking For Exit